Goodfellow says the tie-up is a significant endorsement of their ImmunoBody platform – the underlying technology behind both SCIB1 and SCIB2 - which helps to prime a patient’s immune system to recognise and kill specific cancer cells.
Cancer Research UK collaboration 'a stunning endorsement' for Scancell
Quick facts: Scancell Holdings PLC
Price: 6.069 GBX
Market Cap: £28.24 m
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Scancell Holdings PLC named herein, including the promotion by the Company of Scancell Holdings PLC in any Content on the Site, the Company...FOR OUR FULL DISCLAIMER CLICK HERE